Literature DB >> 22365058

Ganglion cell loss in relation to visual disability in multiple sclerosis.

Scott D Walter1, Hiroshi Ishikawa, Kristin M Galetta, Reiko E Sakai, Daniel J Feller, Sam B Henderson, James A Wilson, Maureen G Maguire, Steven L Galetta, Elliot Frohman, Peter A Calabresi, Joel S Schuman, Laura J Balcer.   

Abstract

PURPOSE: We used high-resolution spectral-domain optical coherence tomography (SD-OCT) with retinal segmentation to determine how ganglion cell loss relates to history of acute optic neuritis (ON), retinal nerve fiber layer (RNFL) thinning, visual function, and vision-related quality of life (QOL) in multiple sclerosis (MS).
DESIGN: Cross-sectional study. PARTICIPANTS: A convenience sample of patients with MS (n = 122; 239 eyes) and disease-free controls (n = 31; 61 eyes). Among MS eyes, 87 had a history of ON before enrollment.
METHODS: The SD-OCT images were captured using Macular Cube (200×200 or 512×128) and ONH Cube 200×200 protocols. Retinal layer segmentation was performed using algorithms established for glaucoma studies. Thicknesses of the ganglion cell layer/inner plexiform layer (GCL+IPL), RNFL, outer plexiform/inner nuclear layers (OPL+INL), and outer nuclear/photoreceptor layers (ONL+PRL) were measured and compared in MS versus control eyes and MS ON versus non-ON eyes. The relation between changes in macular thickness and visual disability was also examined. MAIN OUTCOME MEASURES: The OCT measurements of GCL+IPL and RNFL thickness; high contrast visual acuity (VA); low-contrast letter acuity (LCLA) at 2.5% and 1.25% contrast; on the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) and 10-Item Neuro-Ophthalmic Supplement composite score.
RESULTS: Macular RNFL and GCL+IPL were significantly decreased in MS versus control eyes (P<0.001 and P = 0.001) and in MS ON versus non-ON eyes (P<0.001 for both measures). Peripapillary RNFL, macular RNFL, GCL+IPL, and the combination of macular RNFL+GCL+IPL were significantly correlated with VA (P≤0.001), 2.5% LCLA (P<0.001), and 1.25% LCLA (P≤0.001). Among OCT measurements, reductions in GCL+IPL (P<0.001), macular RNFL (P = 0.006), and the combination (macular RNFL+GCL+IPL; P<0.001) were most strongly associated with lower (worse) NEI-VFQ-25 and 10-Item Supplement QOL scores; GCL+IPL thinning was significant even accounting for macular RNFL thickness (P = 0.03 for GCL+IPL, P = 0.39 for macular RNFL).
CONCLUSIONS: We demonstrated that GCL+IPL thinning is most significantly correlated with both visual function and vision-specific QOL in MS, and may serve as a useful structural marker of disease. Our findings parallel those of magnetic resonance imaging studies that show gray matter disease is a marker of neurologic disability in MS. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22365058      PMCID: PMC3631566          DOI: 10.1016/j.ophtha.2011.11.032

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  46 in total

Review 1.  Grey matter pathology in clinically early multiple sclerosis: evidence from magnetic resonance imaging.

Authors:  Declan Chard; David Miller
Journal:  J Neurol Sci       Date:  2009-02-06       Impact factor: 3.181

2.  Retinal nerve fiber layer thickness and spatial and temporal contrast sensitivity in multiple sclerosis.

Authors:  Harold Merle; Stephane Olindo; Angelique Donnio; Laurence Beral; Raymond Richer; Didier Smadja; Philippe Cabre
Journal:  Eur J Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 2.597

Review 3.  Axonal degeneration in multiple sclerosis: the mitochondrial hypothesis.

Authors:  Kimmy G Su; Gary Banker; Dennis Bourdette; Michael Forte
Journal:  Curr Neurol Neurosci Rep       Date:  2009-09       Impact factor: 5.081

4.  Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration.

Authors:  Ari J Green; Stephen McQuaid; Stephen L Hauser; Ingrid V Allen; Roy Lyness
Journal:  Brain       Date:  2010-04-21       Impact factor: 13.501

5.  Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis.

Authors:  Bryn M Burkholder; Benjamin Osborne; Michael J Loguidice; Esther Bisker; Teresa C Frohman; Amy Conger; John N Ratchford; Christina Warner; Clyde E Markowitz; Dina A Jacobs; Steven L Galetta; Gary R Cutter; Maureen G Maguire; Peter A Calabresi; Laura J Balcer; Elliot M Frohman
Journal:  Arch Neurol       Date:  2009-11

6.  Comparison of spectral/Fourier domain optical coherence tomography instruments for assessment of normal macular thickness.

Authors:  Alan C Sull; Laurel N Vuong; Lori Lyn Price; Vivek J Srinivasan; Iwona Gorczynska; James G Fujimoto; Joel S Schuman; Jay S Duker
Journal:  Retina       Date:  2010-02       Impact factor: 4.256

7.  A topology-preserving approach to the segmentation of brain images with multiple sclerosis lesions.

Authors:  Navid Shiee; Pierre-Louis Bazin; Arzu Ozturk; Daniel S Reich; Peter A Calabresi; Dzung L Pham
Journal:  Neuroimage       Date:  2009-09-17       Impact factor: 6.556

8.  Effects of age on optical coherence tomography measurements of healthy retinal nerve fiber layer, macula, and optic nerve head.

Authors:  Kyung Rim Sung; Gadi Wollstein; Richard A Bilonick; Kelly A Townsend; Hiroshi Ishikawa; Larry Kagemann; Robert J Noecker; James G Fujimoto; Joel S Schuman
Journal:  Ophthalmology       Date:  2009-04-19       Impact factor: 12.079

Review 9.  Imaging outcomes for neuroprotection and repair in multiple sclerosis trials.

Authors:  Frederik Barkhof; Peter A Calabresi; David H Miller; Stephen C Reingold
Journal:  Nat Rev Neurol       Date:  2009-05       Impact factor: 42.937

10.  Detection of macular ganglion cell loss in glaucoma by Fourier-domain optical coherence tomography.

Authors:  Ou Tan; Vikas Chopra; Ake Tzu-Hui Lu; Joel S Schuman; Hiroshi Ishikawa; Gadi Wollstein; Rohit Varma; David Huang
Journal:  Ophthalmology       Date:  2009-09-10       Impact factor: 12.079

View more
  121 in total

1.  Functional-structural correlations in the afferent visual pathway in pediatric demyelination.

Authors:  E Ann Yeh; Ruth Ann Marrie; Y Arun Reginald; J Raymond Buncic; Austin E Noguera; Julia O'Mahony; Jean K Mah; Brenda Banwell; Fiona Costello
Journal:  Neurology       Date:  2014-10-31       Impact factor: 9.910

2.  Roles of Treg/Th17 Cell Imbalance and Neuronal Damage in the Visual Dysfunction Observed in Experimental Autoimmune Optic Neuritis Chronologically.

Authors:  Yuanyuan Liu; Caiyun You; Zhuhong Zhang; Jingkai Zhang; Hua Yan
Journal:  Neuromolecular Med       Date:  2015-08-30       Impact factor: 3.843

Review 3.  Arginase: an old enzyme with new tricks.

Authors:  Ruth B Caldwell; Haroldo A Toque; S Priya Narayanan; R William Caldwell
Journal:  Trends Pharmacol Sci       Date:  2015-04-27       Impact factor: 14.819

4.  [New aspects in the therapy of multiple sclerosis and optic neuritis].

Authors:  W Lagrèze; R Diem
Journal:  Ophthalmologe       Date:  2014-08       Impact factor: 1.059

5.  Evaluation of inner retinal layers in eyes with temporal hemianopic visual loss from chiasmal compression using optical coherence tomography.

Authors:  Mário L R Monteiro; Kenzo Hokazono; Danilo B Fernandes; Luciana V F Costa-Cunha; Rafael M Sousa; Ali S Raza; Diane L Wang; Donald C Hood
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-24       Impact factor: 4.799

6.  Association of body mass index with longitudinal rates of retinal atrophy in multiple sclerosis.

Authors:  Angeliki G Filippatou; Jeffrey Lambe; Elias S Sotirchos; Kathryn C Fitzgerald; Andrew Aston; Olwen C Murphy; Nicole Pellegrini; Nicholas Fioravante; Hunter Risher; Esther Ogbuokiri; Ohemaa Kwakyi; Brandon Toliver; Simidele Davis; Nicholas Luciano; Ciprian Crainiceanu; Jerry L Prince; Ellen M Mowry; Peter A Calabresi; Shiv Saidha
Journal:  Mult Scler       Date:  2020-04-16       Impact factor: 6.312

Review 7.  Evolution of Visual Outcomes in Clinical Trials for Multiple Sclerosis Disease-Modifying Therapies.

Authors:  Rachel C Nolan; Omar Akhand; John-Ross Rizzo; Steven L Galetta; Laura J Balcer
Journal:  J Neuroophthalmol       Date:  2018-06       Impact factor: 3.042

Review 8.  Retinal ganglion cell analysis in multiple sclerosis and optic neuritis: a systematic review and meta-analysis.

Authors:  Josefine Britze; Gorm Pihl-Jensen; Jette Lautrup Frederiksen
Journal:  J Neurol       Date:  2017-05-31       Impact factor: 4.849

9.  Discriminative power of intra-retinal layers in early multiple sclerosis using 3D OCT imaging.

Authors:  Caspar B Seitz; Amgad Droby; Lena Zaubitzer; Julia Krämer; Mathieu Paradis; Luisa Klotz; Heinz Wiendl; Sergiu Groppa; Sven G Meuth; Frauke Zipp; Vinzenz Fleischer
Journal:  J Neurol       Date:  2018-08-02       Impact factor: 4.849

Review 10.  Imaging as an Outcome Measure in Multiple Sclerosis.

Authors:  Daniel Ontaneda; Robert J Fox
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.